Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist

The Journal of Clinical Endocrinology and Metabolism
R J ChangH L Judd

Abstract

The principal glandular source of increased serum androgens in polycystic ovarian disease (PCO) is controversial), since complete separation of ovarian from adrenal function has not been achieved. The purpose of this study was to determine whether a long-acting GnRH agonist could be used to selectively inhibit ovarian steroid secretion in PCO and ovulatory women. Each of five typical PCO patients and six ovulatory subjects on day 2 of their menstrual cycles received D-Trp6-Pro9-NEt-LHRH (GnRH-a; 100 micrograms) for 28 consecutive days. Their results were compared to basal serum hormone values in eight oophorectomized women. In response to GnRH-a, PCO and normal subjects exhibited sharp and sustained rises of LH and gradual decreases in FSH. These levels were clearly less than basal levels seen in oophorectomized women. Episodic LH release was significantly attenuated in both groups at the end of GnRH-a treatment. After the administration of agonist, serum estradiol (E2), estrone (E1), androstenedione (A), and testosterone (T) were suppressed to castrate levels in both groups. The decrements of E2 and E1 in PCO were gradual and continuous compared to initial dramatic rises, which reached peaks at 14 days, and subsequent abrupt f...Continue Reading

Citations

Jun 1, 1985·Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception·L R BeckR M Gilley
Jun 1, 1995·Obstetrics and Gynecology·E CarminaR A Lobo
Nov 1, 1989·Medical Hypotheses·R Kazer
Mar 12, 2004·Metabolism: Clinical and Experimental·Marzieh SalehiLeonid Poretsky
May 20, 1998·Fertility and Sterility·R AzzizL R Boots
Dec 26, 2001·Archives of Medical Research·M BarontiniJ D Veldhuis
Jan 29, 1999·Endocrinology and Metabolism Clinics of North America·A E Taylor
Jun 3, 1999·Endocrinology and Metabolism Clinics of North America·R L Rosenfield
Jun 3, 1999·Endocrinology and Metabolism Clinics of North America·J C Marshall, C A Eagleson
Dec 22, 1999·Journal de gynécologie, obstétrique et biologie de la reproduction·R GandarD Collin
Apr 1, 1996·Baillière's Clinical Endocrinology and Metabolism·S FranksR Williamson
Apr 1, 1996·Baillière's Clinical Endocrinology and Metabolism·S G Soule
Apr 1, 1996·Baillière's Clinical Endocrinology and Metabolism·A Kyei-MensahS Campbell
Sep 1, 1988·Baillière's Clinical Obstetrics and Gynaecology·C P West
Jul 27, 1999·The Journal of Steroid Biochemistry and Molecular Biology·S FranksC Gilling-Smith
Aug 2, 2003·BJOG : an International Journal of Obstetrics and Gynaecology·Stella R MilsomAlistair J Gunn
Sep 26, 2007·Nature Clinical Practice. Endocrinology & Metabolism·R Jeffrey Chang
Mar 2, 1989·The New England Journal of Medicine·R B BarnesD A Ehrmann
Jan 20, 1991·The New England Journal of Medicine·P M Conn, W F Crowley
Jul 16, 1992·The New England Journal of Medicine·D A EhrmannZ Sheikh
Sep 28, 1995·The New England Journal of Medicine·S Franks
Nov 1, 1994·Clinical Endocrinology·A Kyei-Mensah, H S Jacobs
Jun 24, 1998·British Journal of Obstetrics and Gynaecology·A Pickersgill
Mar 1, 1994·American Journal of Reproductive Immunology : AJRI·M H GoniG Tolis
Sep 1, 1989·Archives of Disease in Childhood·C F ClarkeD Grant
Jan 1, 1994·Annual Review of Medicine·P M Conn, W F Crowley
Jun 1, 2010·Therapeutic Advances in Endocrinology and Metabolism·Hany Lashen
Nov 13, 2001·American Journal of Clinical Dermatology·L FalsettiL Legrenzi
Dec 18, 1998·Journal of Endocrinological Investigation·J C Marshall
Jan 26, 2010·Annales d'endocrinologie·Anne BachelotMarie-Béatrice Galand-Portier
Feb 1, 1990·Journal of Behavioral Medicine·L C SwartzmanE Kemmann
Feb 15, 2002·Human Fertility : Journal of the British Fertility Society·Stephen FranksMark McCarthy
Mar 24, 2012·Expert Opinion on Emerging Drugs·Isabelle StreuliCharles Chapron
Jan 5, 2002·Expert Opinion on Investigational Drugs·P Moghetti
Feb 28, 2002·Expert Opinion on Investigational Drugs·Enrico Carmina
Mar 5, 2016·Gynecologic Oncology Reports·Ilan CohenAmi Fishman
Jun 1, 1986·American Journal of Obstetrics and Gynecology·K A SteingoldR J Chang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.